“Renal Cell Carcinoma With Leiomyomatous Stroma” Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity

结节性硬化 病理 肾细胞癌 基质 生物 TSC1 清除单元格 免疫组织化学 癌症研究 透明细胞癌 PI3K/AKT/mTOR通路 医学 遗传学 细胞凋亡
作者
Rajal B. Shah,Bradley A. Stohr,Zheng Jin Tu,Yuan Gao,Christopher G. Przybycin,Jane Nguyen,Roni M. Cox,Fariborz Rashid-Kolvear,Michael Weindel,Daniel H. Farkas,Kiril Trpkov,Jesse K. McKenney
出处
期刊:The American Journal of Surgical Pathology [Lippincott Williams & Wilkins]
卷期号:44 (5): 571-581 被引量:84
标识
DOI:10.1097/pas.0000000000001422
摘要

Renal cell carcinoma with (angio) leiomyomatous stroma (RCCLMS) is included as a provisional entity in the 2016 World Health Organization (WHO) classification of renal epithelial neoplasia; however, debate remains whether it represents a distinct entity or a heterogenous group of renal cell carcinomas (RCCs) with overlapping morphology. Also, its relationship to similar tumors occurring in the setting of tuberous sclerosis complex (TSC) is not fully addressed. We analyzed the clinicopathologic, immunohistochemical, and molecular characteristics of 23 sporadic RCCs associated with smooth muscle stroma and classified them into 2 groups, independent of molecular results: (1) RCCLMS (n=18) and (2) clear cell renal cell carcinoma (CCRCC) (n=5). The classification of a case as “RCCLMS” was based on morphologic comparison with 5 “index” RCCs from 3 patients with TSC showing similar features and the presence of diffuse CK7 expression. To investigate mutational and copy number alterations, a 170-gene solid tumor panel was utilized to sequence 14 RCCLMSs and control of 5 CCRCCs. Also, 4 RCCLMSs, suspicious for chromosome 8 monosomy, were further evaluated by a broader 479 gene sequencing panel that included ELOC (also referred to as TCEB1 ). Clinical information and follow-up data were obtained from electronic medical records. The mean age of patients with RCCLMS was 52 years (range, 33 to 69) with male:female ratio of 1:2. Macroscopically, all tumors were solitary and predominantly (82%) tan/red, circumscribed, and solid. The average tumor size was 2.3 cm (range, 1.1 to 4.5). Microscopically, the distinctive feature included tumor nodules of elongated and frequently branching tubules lined by cells with voluminous clear to mildly eosinophilic cytoplasm (100%), separated by focal to prominent smooth muscle stroma. Additional frequently identified features included: biphasic pattern of collapsed acini surrounding tubules with voluminous cytoplasm (50%), focal papillary architecture (39%), peritumoral lymphoid aggregates (39%), and hemosiderin-laden macrophages (33%). All 11 (100%) RCCLMSs with available staging information were pT1; 78% were WHO/International Society of Urologic Pathology (ISUP) grade 2 and 22% grade 3. Immunophenotypically, RCCLMSs were characterized by diffuse CK7, CAM5.2 and CD10 reactivity (100%). All patients with available follow-up (n=10) were alive and without disease progression after a mean and median follow-up of 25.2 (range: 1 to 58) and 25 months, respectively. The molecular results showed recurrent mutations in all RCCLMS: TSC1 (4), TSC2 (4), MTOR (6), and/or ELOC (2). Five control CCRCCs demonstrated primary alterations in VHL gene, while all 14 RCCLMS cases tested had intact VHL gene. Of 2 RCCLMSs with confirmed monosomy 8, 1 showed a hotspot ELOC mutation without TSC/MTOR mutations, and 1 showed a previously undescribed 3-bp in-frame ELOC deletion, along with a truncating TSC1 mutation. In conclusion, RCCLMS, as defined herein, harbors recurrent mutations of TSC1 / TSC2 , MTOR , and/or ELOC , consistent with hyperactive MTOR complex. Our findings argue that these tumors represent the sporadic counterpart to morphologically identical tumors occurring in TSC patients. Finally, the data support that RCCLMS is a novel subtype of RCC with unique morphologic, immunohistochemical, and molecular characteristics that is distinct from CCRCC and clear cell-papillary RCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CHensby完成签到,获得积分10
1秒前
细心的盼易完成签到 ,获得积分10
1秒前
英俊的含蕾完成签到 ,获得积分10
2秒前
龙行天下完成签到,获得积分10
4秒前
小蘑菇应助WN采纳,获得10
5秒前
6秒前
6秒前
东郭一斩完成签到,获得积分10
6秒前
量子星尘发布了新的文献求助10
6秒前
平安喜乐发布了新的文献求助10
7秒前
左孤容完成签到 ,获得积分10
7秒前
wanmiao12完成签到,获得积分10
9秒前
yu发布了新的文献求助10
10秒前
mmmmm完成签到,获得积分10
11秒前
洁净白容完成签到,获得积分10
11秒前
大个应助孟孟采纳,获得10
11秒前
小镇的废物完成签到,获得积分10
11秒前
柴郡喵完成签到,获得积分10
12秒前
SYLH应助小熊采纳,获得10
13秒前
妹妹发布了新的文献求助10
13秒前
13秒前
赘婿应助我必定发nature采纳,获得20
14秒前
Ava应助kofbird采纳,获得50
15秒前
zz完成签到,获得积分10
15秒前
星辰大海应助ybwei2008_163采纳,获得10
15秒前
17秒前
17秒前
QJYKKK完成签到,获得积分10
17秒前
composite66完成签到,获得积分10
17秒前
ccchao发布了新的文献求助30
18秒前
充电宝应助十三采纳,获得10
18秒前
大个应助橙橙橙采纳,获得10
18秒前
Dandanhuang完成签到,获得积分10
18秒前
FashionBoy应助孟孟采纳,获得30
20秒前
畅快的刚完成签到,获得积分10
22秒前
22秒前
xxxx完成签到,获得积分10
22秒前
vain发布了新的文献求助10
22秒前
李健应助芒果小鹌鹑采纳,获得10
22秒前
cc完成签到,获得积分10
23秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038569
求助须知:如何正确求助?哪些是违规求助? 3576279
关于积分的说明 11374944
捐赠科研通 3305979
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815048